Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis

Figure 1 Overall survival rates of patients with advanced gastric cancer in 12 studies (A), 3-year progression-free rates in 3 studies (B), tomor down-staging rates in 6 studies (C), R0 resection rates in 8 studies (D), and adverse effects of neoadjuvant chemotherapy (E). NAC: Neoadjuvant chemotherapy; PFS: Progression-free survival; CI: Confidence interval.

Figure 2 Subgroup analysis showing different overall survival rates of patients with advanced gastric cancer in trials from Western and Asian counties. NAC: Neoadjuvant chemotherapy; IV: Intravenous; IA: Intra-arterial.

Figure 3 Odds ratio (A) and publication bias (B) in studies included in this study. A: Sensitivity analysis for overall survival: high-quality studies (Jadad score ≥ 4); B: Funnel plot analysis of potential publication bias.